Jefferies Financial Group provided analyst ratings for AstraZeneca stock on June 20, 2026.
7 reports, 3 independent
Updated Oct 12
Gone quiet
- Reports
- 7
- Developments
- 4
- Repetition
- 43%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Jefferies Financial Group provided analyst ratings for AstraZeneca stock on June 20, 2026.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Multiple firms, including Amundi and RBC, updated their ratings and positions on AstraZeneca stock.1 source
Jefferies reissued a buy rating on AstraZeneca stock on August 16, 2026.1 source
Amundi increased its stake in AstraZeneca shares alongside Jefferies reaffirming a buy rating.1 source
Jefferies Financial Group issued analyst ratings for AstraZeneca.1 source
Keep exploring
The entities involved
-
Jefferies Financial Group
American financial services company
-
AstraZeneca
British-Swedish pharmaceutical company
Related events
- Jefferies Financial Group cut the stock rating for Carlsberg Group to 'hold' on October 13, 2026.
- Jefferies Financial Group reaffirmed a Buy rating on London Stock Exchange Group.
- AstraZeneca listed shares on the New York Stock Exchange to attract investors.
- Jefferies upgraded its rating on OSRAM, influencing market sentiment regarding the company.
- Jefferies started coverage with a buy rating on Formula One Group, while MarketBeat provided the average stock rating.